alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 812.30 FDA action on applications. ( a ) *Approval or disapproval.* FDA will notify the sponsor in writing of the date it receives an application. FDA may approve an investigation as proposed, approve it with modifications, or disapprove it. An investigation may not begin until: ( 1 ) Thirty days after FDA receives the application at the address in § 812.19 for the investigation of a device other than a banned device, unless FDA notifies the sponsor that the investigation may not begin; or
( 2 ) FDA approves, by order, an IDE for the investigation.
( b ) *Grounds for disapproval or withdrawal.* FDA may disapprove or withdraw approval of an application if FDA finds that: ( 1 ) There has been a failure to comply with any requirement of this part or the act, any other applicable regulation or statute, or any condition of approval imposed by an IRB or FDA.
( 2 ) The application or a report contains an untrue statement of a material fact, or omits material information required by this part.
( 3 ) The sponsor fails to respond to a request for additional information within the time prescribed by FDA.
( 4 ) There is reason to believe that the risks to the subjects are not outweighed by the anticipated benefits to the subjects and the importance of the knowledge to be gained, or informed consent is inadequate, or the investigation is scientifically unsound, or there is reason to believe that the device as used is ineffective.
( 5 ) It is otherwise unreasonable to begin or to continue the investigation owing to the way in which the device is used or the inadequacy of: ( i ) The report of prior investigations or the investigational plan;
( ii ) The methods, facilities, and controls used for the manufacturing, processing, packaging, storage, and, where appropriate, installation of the device; or
( iii ) Monitoring and review of the investigation.
( c ) *Notice of disapproval or withdrawal.* If FDA disapproves an application or proposes to withdraw approval of an application, FDA will notify the sponsor in writing. ( 1 ) A disapproval order will contain a complete statement of the reasons for disapproval and a statement that the sponsor has an opportunity to request a hearing under part 16.
( 2 ) A notice of a proposed withdrawal of approval will contain a complete statement of the reasons for withdrawal and a statement that the sponsor has an opportunity to request a hearing under part 16. FDA will provide the opportunity for hearing before withdrawal of approval, unless FDA determines in the notice that continuation of testing under the exemption will result in an unreasonble risk to the public health and orders withdrawal of approval before any hearing.
[45 FR 3751, Jan. 18, 1980, as amended at 45 FR 58842, Sept. 5, 1980]
Reserve RD

Quemado RD

Reserve RD

Glenwood RD

Quemado RD

Glenwood RD

Quemado RD

Springerville RD

Greenlee County

Catron County

Apache County

Catron County

Lower San

Francisco

Plaza

Luna

Reserve

San

Francisco

Plaza

anozirA

ocixeM weN

Luna Planning Area

Luna (185,586 ac.)

! City/Town

National Forest Boundary

County Boundary

Ranger District Boundary

Private Ownership

Luna Planning Area Fire Potential

Fire Type (% Area)

No Fire (3%)

Surface Fire (29%)

Torching/Passive Crown Fire (48%)

Active Crown Fire (20%)

LUNA RESTORATION PROJECT

0 1 2 4

Miles

Created On: 5/11/2016 1:14:46 PM

Coordinate System: NAD 1983 UTM Zone 12NTransverse Mercator

o 1 in = 2 miles

1:125,000

(printed on 11" x 17" portrait layout)

Created By: jjelacic

The USDA is an equal opportunity provider, employer, and lender

and

MAP 1 - Fire potential within the 

planning area displaying the

areas of potential surface fire 

torching/passive and active
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

                    By Notice dated October 21, 2009, and published in the                     **Federal Register**                     on October 28, 2009 (74 FR 55584), Hospira Inc., 1776 North Centennial Drive, McPherson, Kansas 67460-1247, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Remifentanil (9739), a basic class of controlled substance listed in schedule II.                

The company plans to import Remifentanil for use in dosage form manufacturing.

                    No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Hospira Inc. to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international                           ( print page 10313)                        treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Hospira Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.                

Dated: February 26, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010-4770 Filed 3-4-10; 8:45 am]

BILLING CODE 4410-09-P
# C_2014135EN.01004901.xml

| 5.5.2014 | EN | Official Journal of the European Union | C 135/49 |
| --- | --- | --- | --- |

5.5.2014

EN

Official Journal of the European Union

C 135/49

---

Action brought on 10 February 2014 — Export Development Bank of Iran v Council

(Case T-89/14)

2014/C 135/63

Language of the case: French

Parties

Parties

Applicant: Export Development Bank of Iran (Tehran, Iran) (represented by: J.-M. Thouvenin, lawyer)

Applicant:

Defendant: Council of the European Union

Defendant:

Form of order sought

Form of order sought

The applicant claims that the General Court should:

| — | annul Council Implementing Regulation (EU) No 1154/2013 of 15 November 2013 in so far as it concerns the applicant; |
| --- | --- |

—

annul Council Implementing Regulation (EU) No 1154/2013 of 15 November 2013 in so far as it concerns the applicant;

| — | annul Council Decision 2013/661/CFSP of 15 November 2013 in so far as it concerns the applicant; |
| --- | --- |

—

annul Council Decision 2013/661/CFSP of 15 November 2013 in so far as it concerns the applicant;

| — | declare Council Regulation (EU) No 267/2012 of 23 March 2012 inapplicable to the applicant; |
| --- | --- |

—

declare Council Regulation (EU) No 267/2012 of 23 March 2012 inapplicable to the applicant;

| — | declare decision 2010/413 CFSP inapplicable to the applicant; |
| --- | --- |

—

declare decision 2010/413 CFSP inapplicable to the applicant;

| — | in the alternative, annul the implementing regulation and the decision mentioned in the first two indents of the present form of order, as from 20 January 2014; |
| --- | --- |

—

in the alternative, annul the implementing regulation and the decision mentioned in the first two indents of the present form of order, as from 20 January 2014;

| — | order the Council to pay the costs. |
| --- | --- |

—

order the Council to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

In support of its action, the applicant relies on nine pleas in law of which eight are essentially identical or similar to those advanced in Case T-65/14 Bank Refah Kargaran v Council.

Bank Refah Kargaran

Council

Furthermore the applicant relies on a plea in law alleging infringement of the principles of equality and of non-discrimination.

---
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2190 Henna. ( a ) *Identity.* The color additive henna is the dried leaf and petiole of *Lawsonia alba* Lam. (*Lawsonia inermis* L.). It may be identified by its characteristic odor and by characteristic plant histology.
( b ) *Specifications.* Henna shall conform to the following specifications: It shall not contain more than 10 percent of plant material from *Lawsonia alba* Lam. (*Lawsonia inermis* L.) other than the leaf and petiole, and shall be free from admixture with material from any other species of plant. Moisture, not more than 10 percent. Total ash, not more than 15 percent. Acid-insoluble ash, not more than 5 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million.
( c ) *Uses and restrictions.* The color additive henna may be safely used for coloring hair only. It may not be used for coloring the eyelashes or eyebrows, or generally in the area of the eye.
( d ) *Labeling.* The label for henna shall bear the information required by § 70.25 of this chapter and the following statements or their equivalent: “Do not use in the area of the eye.” “Do not use on cut or abraded scalp.”
( e ) *Exemption from certification.* Certification of this color additive for the prescribed use is not necessary for the protection of the public health and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
<PAGE>   1
                                                                    EXHIBIT 21.1





                                    -111-
<PAGE>   2

                             HARBINGER CORPORATION
                              LIST OF SUBSIDIARIES



                     Comtech Management Systems, Inc.

                     EDI Integration Services Limited

                     Harbinger N.V.

                     Harbinger Ltd. (UK)

                     Omega GmbH

                     INOVIS GmbH & Co.

                     NTEX Holdings B.V.

                     NTEX Computer Centrum, B.V.

                     NTEX Datacommunications, B.V.

                     SupplyTech, Inc.

                     SupplyTech International, LLC

                     SupplyTech de Mexico, S.A. de C.V.

                     SupplyTech International S.r.L.




                                    -112-
<PAGE>   1

                                                              EXHIBIT 15



INDEPENDENT PUBLIC ACCOUNTANTS' AWARENESS LETTER


February 12, 1997


Essef Corporation and Subsidiaries
220 Park Drive
Chardon, Ohio


We have made a review, in accordance with standards established by the American
Institute of Certified Public Accountants, of the unaudited interim financial
information of Essef Corporation and Subsidiaries for the periods ended December
31, 1996 and 1995, as indicated in our report dated January 23, 1997; because we
did not do an audit, we expressed no opinion on that information.

We are aware that our report referred to above, which is included in your
Quarterly Report on Form 10-Q for the quarter ended December 31, 1996, is
incorporated by reference in Registration Statement No. 33-17758 on Form S-8.

We also are aware that the aforementioned report, pursuant to Rule 436(c) under
the Securities Act of 1933, is not considered a part of the Registration
Statement prepared or certified by an accountant or a report prepared or
certified by an accountant within the meaning of Sections 7 and 11 of that Act.






DELOITTE & TOUCHE

Cleveland, Ohio















                                  Page 16 of 16
§ 582.2122 Aluminum calcium silicate. ( a ) *Product.* Aluminum calcium silicate.
( b ) *Tolerance.* 2 percent.
( c ) *Limitations, restrictions, or explanation.* This substance is generally recognized as safe when used in table salt in accordance with good manufacturing or feeding practice.
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER  Pursuant to 18 U.S.C. Section 1350, as adopted  Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned, John P. Wilmers, Chief Executive Officer of Ballantyne of Omaha, Inc. (the "Company"), has executed this certification
in connection with the filing with the Securities and Exchange Commission of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (the "Report").

The
undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to his knowledge
that:



IN
WITNESS WHEREOF, the undersigned has executed this certification as of the 27th day of March 2009.

/s/ JOHN P. WILMERS John P. Wilmers
Chief Executive Officer


A
signed original of this written statement required by Section 906 has been provided to Ballantyne of Omaha, Inc. and will be retained by Ballantyne of Omaha, Inc. and furnished to the
Securities and Exchange Commission or its staff upon request.

---



QuickLinks
## Court of Appeals Sixth Appellate District of Texas

J U D G M E N T

Bryan Keith Lynch , Appellant

No. 06

- 23

- 00111

- CR v.

The State of Texas , Appellee Appeal from the 6th District Court of

Lamar County, Texas (Tr. Ct. No. 28257 ). Memorandum Opinion delivered by Justice

Rambin

, Chief Justice Stevens and Justice

van Cleef participating.

As stated in the Court’s opinion of this date, we find that the appeal should be dismissed

for want of jurisdiction . Therefore, we dismiss the appeal.

We note tha t the appellant, Bryan Keith Lynch , has adequately indicated his inability to

pay costs of appeal. Therefore, we waive payment of costs.

RENDERED AUGUS T 15 , 2023
BY ORDER OF THE COURT
SCOTT E. STEVENS
CHIEF JUSTICE

ATTEST: Debra K. Autrey , Clerk
<PAGE>   1
                                                                   EXHIBIT 10.14


                                 AMENDMENT NO. 2
                                       TO
                          EQUIPMENT PURCHASE AGREEMENT

                  Reference is hereby made to that Equipment Purchase Agreement
(the "Agreement") effective as of December 1, 1995 between PageMart Wireless,
Inc. ("PageMart") and Motorola, Inc. ("Motorola"). Capitalized terms used but
not otherwise defined herein shall have the meanings ascribed thereto in the
Agreement.

                  WHEREAS, PageMart and Motorola have agreed to modify the
Agreement;

                  NOW THEREFORE, the parties hereby agree as follows:

ARTICLE IV: SECTION 1.3 CREDIT FOR ADVANCED MESSAGING SUBSCRIBER UNITS, IS
HEREBY AMENDED TO READ IN ITS ENTIRETY, AS FOLLOWS:

         1.3 Credit for Advanced Messaging Subscriber Units. As described here
and in Article III, Section 1, as additional consideration for the transfer of
the PageMart Patents to Motorola in accordance with the Technology Asset
Agreement between the parties, Motorola agrees to furnish at no cost to
PageMart, credit for an additional $1.5 million of two-way advanced messaging
subscriber equipment (priced at the purchase prices of this Agreement), applied
on a pro-rata basis to PageMart's purchase of its first $5 million of two-way
messaging subscriber Equipment from Motorola during the term of this Agreement.
PageMart will be entitled to credit each month for a proportionate amount of
subscriber Equipment in addition to the first $5 million, based upon the
subscriber Equipment purchased to date through that month.

PageMart has issued to Motorola an initial Purchase Order for 5,000 (five
thousand) ReFLEX25 advanced messaging subscriber units and will provide one or
more additional Purchase Orders for 20,000 (twenty thousand) ReFLEX25 advanced
messaging units, when they are commercially available. Since Motorola has been
unable to deliver and certify as commercial by June 15, 1998, the ReFLEX25
advanced messaging subscriber Equipment in the first Purchase Order, the October
31, 1999 date in Section 1.1 of Article IV of the Agreement shall be extended
for the period of time that commercial availability is delayed beyond June 15,
1998, up to a maximum extension of one year.


Date of Modification: August 5, 1998




PAGEMART WIRELESS, INC.                    MOTOROLA, INC.

By: /s/ N. ROSS BUCKERHAM                  By: /s/ JULIE A. SHIMER
   ------------------------------             ----------------------------------
Name: N. Ross Buckerham                    Name: Julie A. Shimer
     ----------------------------               --------------------------------
Title: President                           Title: VP & GM NAPSD
      ---------------------------                -------------------------------
Date: 8/15/98                              Date: 8/5/98
     ----------------------------               --------------------------------
**Exhibit 32**

**CertificationPursuant to 18 U.S.C. Section 1350 as AdoptedPursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection withthe Annual Report of AXS-One Inc. (the “Company”) on Form 10-K for theyear ended December 31, 2004, as filed with the Securities and ExchangeCommission on the date hereof (the “Report”), each of the undersigned officersof the Company certifies pursuant to 18 U.S.C. Section1350, as adopted pursuantto Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of suchofficer’s knowledge:

1.                The Report fullycomplies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934, and

2.                Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.
|                                           | AXS-ONE INC. |
|-------------------------------------------|--------------|
| **Date:  **March 31,  2005 | By:          | /s/ WILLIAM P. LYONS |
|                                      |         | William P. Lyons |
|                                      |         | *Chairman of the Board and Chief Executive Officer* |
|                                      | By:          | /s/ JOSEPH DWYER |
|                                      |         | Joseph Dwyer |
|                                      |         | *Executive Vice President, Chief Financial  Officer, and Treasurer* |

 

1

----
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                          12,063
<INT-BEARING-DEPOSITS>                           8,089
<FED-FUNDS-SOLD>                                 4,100
<TRADING-ASSETS>                                   736
<INVESTMENTS-HELD-FOR-SALE>                     12,591
<INVESTMENTS-CARRYING>                          24,875
<INVESTMENTS-MARKET>                            25,667
<LOANS>                                        149,617
<ALLOWANCE>                                      1,745
<TOTAL-ASSETS>                                 220,493
<DEPOSITS>                                     189,698
<SHORT-TERM>                                         0
<LIABILITIES-OTHER>                              1,104
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        17,836
<OTHER-SE>                                      11,855
<TOTAL-LIABILITIES-AND-EQUITY>                 220,493
<INTEREST-LOAN>                                 12,910
<INTEREST-INVEST>                                1,731
<INTEREST-OTHER>                                   595
<INTEREST-TOTAL>                                15,236
<INTEREST-DEPOSIT>                               5,765
<INTEREST-EXPENSE>                               5,765
<INTEREST-INCOME-NET>                            9,471
<LOAN-LOSSES>                                      735
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  7,535
<INCOME-PRETAX>                                  3,136
<INCOME-PRE-EXTRAORDINARY>                       2,212
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,212
<EPS-PRIMARY>                                      .63
<EPS-DILUTED>                                      .59
<YIELD-ACTUAL>                                    4.78
<LOANS-NON>                                        639
<LOANS-PAST>                                        32
<LOANS-TROUBLED>                                   208
<LOANS-PROBLEM>                                    215
<ALLOWANCE-OPEN>                                 1,296
<CHARGE-OFFS>                                      313
<RECOVERIES>                                        27
<ALLOWANCE-CLOSE>                                1,745
<ALLOWANCE-DOMESTIC>                             1,316
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                            429
        

</TABLE>
###### Editorial Note on Part 112

#### Editorial Note:

Nomenclature changes to part 112 appear at 81 FR 49896, July 29, 2016.

#### §§ 112.48-112.49 [Reserved]
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.96    
  


 
 

EXTENSION AGREEMENT    
  


Bank
of America, N.A.,

    as Administrative Agent

Attn: Suzanne Paul

231 South LaSalle Street

Chicago, Illinois 60604 


Ladies
and Gentlemen: 


        The
undersigned hereby agrees to extend, effective April 3, 2002, its Commitment and the Maturity Date under the Credit Agreement dated as of April 3, 2001 among
SOURCECORP, Incorporated, f/k/a F.Y.I. Incorporated, each of the Lenders party thereto, Bank of America, N.A., as Administrative Agent, and Banc of America Securities LLC, as sole lead arranger and
sole book agent (as the same may be amended or otherwise modified from time to time, the "Credit Agreement") for 364 days to April 2, 2005
pursuant to Section 2.1(d) of the Credit Agreement. Terms defined in the Credit Agreement are used herein as therein defined. 


        This
Extension Agreement shall be construed in accordance with and governed by the law of the State of Texas. The Extension Agreement may be signed in any number of counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 



	

 	
 	
TEXAS CAPITAL BANK, NATIONAL

ASSOCIATION
	

 	
 	

Name:	

/s/ PAUL HOWELL

	 	 	 	By:	Paul Howell

	 	 	 	Title:	Vice President






	

Agreed and Accepted:
	

SOURCECORP, INCORPORATED, f/k/a

F.Y.I. INCORPORATED
	

By:	

/s/ BARRY EDWARDS

	Name:	Barry Edwards

	Title:	EVP & CFO

	

BANK OF AMERICA, N.A., as Administrative Agent
	

By:	

/s/ SUZANNE M. PAUL

	Name:	Suzanne M. Paul
	Title:	Vice President













QuickLinks



Exhibit 10.96


EXTENSION AGREEMENT